Author:
Bhamidipati P K,DiPersio J F,Stokerl-Goldstein K,Rashidi A,Gao F,Uy G L,Westervelt P,Vij R,Schroeder M A,Abboud C N,Keller J W,Fehniger T A,Romee R
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference8 articles.
1. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.
2. Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012; 18: 1859–1866.
3. Grosso D, Carabasi M, Filicko-O'Hara J, Kasner M, Wagner JL, Colombe B et al. A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. Blood 2011; 118: 4732–4739.
4. Dominietto A, Raiola AM, Bruno B, van Lint MT, Frassoni F, Grazia CD et al. Rapid immune reconstitution following unmanipulated haploidentical BMT with post-transplant high dose cyclophosphamide. ASH Annual Meeting Abstracts 2011; 118: 3050.
5. Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013; 19: 117–122.
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献